EARTH CITY, Mo.--(BUSINESS WIRE)--Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the release of “Patient-First Approach Maximizes Therapeutic Benefits of Humatin™ for Treatment of Intestinal Amebiasis.” This white paper highlights how Humatin™ (paromomycin sulfate), available exclusively through Humatin Total Care, brings specialty drug expertise to this patient population and in-depth understanding of this particular disease.
EARTH CITY, Mo.--(BUSINESS WIRE)--Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care. This patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis, a parasitic infection of the intestines caused by the protozoan E. histolytica. According to the most recent report, among patients with amebiasis in the United States 33% were Hispanic immigrants and 17% were Asia or the Pacific Islands immigrants.